- Market Realist•11 hours ago
On March 3, 2017, Amgen announced positive results from its Phase 3 trial 482 study evaluating the efficacy of Xgeva in delaying skeletal-related events or bone complications in multiple myeloma patients....
- Market Realist•12 hours ago
On March 3, 2017, Amgen (AMGN) presented interim data from its Phase 3 trial, ENDEAVOR. The data showed the superiority of a combination therapy of Kyprolis and dexamethasone over Velcade.
- Investor's Business Daily•13 hours ago
Biotech stocks have made big gains in 2017, but not all companies are winners.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||163.10 x 100|
|Ask||163.29 x 200|
|Day's Range||161.53 - 163.47|
|52 Week Range||133.64 - 184.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||15.95|
|Dividend & Yield||4.60 (2.84%)|
|1y Target Est||N/A|